Dostarlimab Shows Durable Antitumor Activity in GARNET Trial Expansion Cohorts With Advanced, Recurrent Endometrial Cancer
Biosensors | Free Full-Text | Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment
Dostarlimab Therapy in Recurrent Metastatic Endometrial Cancer: The GARNET Trial
The comparative clinical effectiveness of dostarlimab versus doxorubicin in the treatment of advanced/recurrent endometrial cancer (216) - ScienceDirect
Antitumor Activity of Dostarlimab in Patients with Mismatch Repair–Deficient (dMMR) Tumors: a Combined Analysis of 2 Cohorts i
Laboratory Abnormalities | JEMPERLI (dostarlimab-gxly)
Cara Mathews, MD, Talks Dostarlimab for Advance Recurrent Endometrial Cancers
Clinical trials testing the combination of drug Dostarlimab with other... | Download Scientific Diagram
The Time Course of Adverse Events During Dostarlimab Treatment in Patients with Recurrent or Advanced Endometrial Cancer in the
GSK announces positive data for endometrial cancer drug dostarlimab - Pharmaceutical Technology
AACR 2022: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I ...
Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer | Future Oncology
PDF) Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
Biomolecules | Free Full-Text | Dostarlimab: A Review
Medicina | Free Full-Text | Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer
Study Design | JEMPERLI (dostarlimab-gxly)
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer - Plain Language Summaries
Jemperli (dostarlimab-gxly) to Treat Advanced Solid Tumours
ONS 2022: Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair deficient solid tumors treated with dostarlimab
Study Design | JEMPERLI (dostarlimab-gxly)
PDF) Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase ...
Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non–small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial - Clinical Lung Cancer
GSK Poster Hub
GARNET Study Suggests Dostarlimab Promising for Uterine/Endometrial Cancer - CancerConnect
